This systematic review and meta-analysis demonstrated that SGLT2 inhibitors provided similar benefits in reducing HF hospitalization or CVD in patients with HFmrEF and HFpEF, primarily driven by their impact on hospitalization for HF [45]. This evidence concerns the gene SLC5A2 and hydrops fetalis.